Abdelsaid Mohammed, Coucha Maha, Hafez Sherif, Yasir Abdul, Johnson Maribeth H, Ergul Adviye
Charlie Norwood Veterans Administration Medical Center, Augusta, GA, USA.
Department of Physiology, Augusta University, 1120 15th Street CA-3135, Augusta, GA, 30912, USA.
Diabetologia. 2017 Apr;60(4):740-750. doi: 10.1007/s00125-017-4214-6. Epub 2017 Jan 23.
AIMS/HYPOTHESIS: Diabetes promotes cerebral neovascularisation via increased vascular endothelial growth factor (VEGF) angiogenic signalling. Roundabout-4 (ROBO4) protein is an endogenous inhibitor of VEGF signalling that stabilises the vasculature. Yet, how diabetes affects ROBO4 function remains unknown. We hypothesised that increased VEGF signalling in diabetes decreases ROBO4 expression and function via binding of ROBO4 with VEGF-activated β3 integrin and that restoration of ROBO4 expression prevents/repairs cerebral neovascularisation in diabetes.
ROBO4 protein expression in a rat model of type 2 diabetes (Goto-Kakizaki [GK] rats) was examined by western blotting and immunohistochemistry. ROBO4 was locally overexpressed in the brain and in primary brain microvascular endothelial cells (BMVECs). GK rats were treated with SKLB1002, a selective VEGF receptor-2 (VEGFR-2) antagonist. Cerebrovascular neovascularisation indices were determined using a FITC vascular space-filling model. Immunoprecipitation was used to determine ROBO4-β3 integrin interaction.
ROBO4 expression was significantly decreased in the cerebral vasculature as well as in BMVECs in diabetes (p < 0.05). Silencing Robo4 increased the angiogenic properties of control BMVECs (p < 0.05). In vivo and in vitro overexpression of ROBO4 inhibited VEGF-induced angiogenic signalling and increased vessel maturation. Inhibition of VEGF signalling using SKLB1002 increased ROBO4 expression (p < 0.05) and reduced neovascularisation indices (p < 0.05). Furthermore, SKLB1002 significantly decreased ROBO4-β3 integrin interaction in diabetes (p < 0.05).
CONCLUSIONS/INTERPRETATION: Our study identifies the restoration of ROBO4 and inhibition of VEGF signalling as treatment strategies for diabetes-induced cerebral neovascularisation.
目的/假设:糖尿病通过增加血管内皮生长因子(VEGF)血管生成信号来促进脑新生血管形成。Roundabout-4(ROBO4)蛋白是VEGF信号的内源性抑制剂,可稳定脉管系统。然而,糖尿病如何影响ROBO4功能仍不清楚。我们假设糖尿病中增加的VEGF信号通过ROBO4与VEGF激活的β3整合素结合来降低ROBO4表达和功能,并且ROBO4表达的恢复可预防/修复糖尿病中的脑新生血管形成。
通过蛋白质印迹法和免疫组织化学检查2型糖尿病大鼠模型(Goto-Kakizaki [GK]大鼠)中ROBO4蛋白的表达。ROBO4在脑和原代脑微血管内皮细胞(BMVEC)中局部过表达。GK大鼠用选择性VEGF受体-2(VEGFR-2)拮抗剂SKLB1002治疗。使用FITC血管空间填充模型确定脑血管新生血管形成指数。免疫沉淀用于确定ROBO4-β3整合素相互作用。
糖尿病时,脑脉管系统以及BMVEC中ROBO4表达显著降低(p <0.05)。沉默Robo4可增加对照BMVEC的血管生成特性(p <0.05)。ROBO4的体内和体外过表达抑制VEGF诱导的血管生成信号并增加血管成熟。使用SKLB1002抑制VEGF信号可增加ROBO4表达(p <0.05)并降低新生血管形成指数(p <0.05)。此外,SKLB1002可显著降低糖尿病中ROBO4-β3整合素的相互作用(p <0.05)。
结论/解读:我们的研究确定恢复ROBO4和抑制VEGF信号作为糖尿病诱导的脑新生血管形成的治疗策略。